000186213 001__ 186213
000186213 005__ 20241230121009.0
000186213 0247_ $$2doi$$a10.1007/s11764-022-01293-x
000186213 0247_ $$2pmid$$apmid:36459378
000186213 0247_ $$2ISSN$$a1932-2259
000186213 0247_ $$2ISSN$$a1932-2267
000186213 0247_ $$2altmetric$$aaltmetric:139621763
000186213 037__ $$aDKFZ-2022-03010
000186213 041__ $$aEnglish
000186213 082__ $$a610
000186213 1001_ $$0P:(DE-He78)2f71c86de1a231d82abb4322a95e172a$$aSchneider, Jana$$b0$$eFirst author
000186213 245__ $$aOut-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: a multi-regional population-based study.
000186213 260__ $$aNew York, NY [u.a.]$$bSpringer$$c2023
000186213 3367_ $$2DRIVER$$aarticle
000186213 3367_ $$2DataCite$$aOutput Types/Journal article
000186213 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697808644_29653
000186213 3367_ $$2BibTeX$$aARTICLE
000186213 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186213 3367_ $$00$$2EndNote$$aJournal Article
000186213 500__ $$a#EA:C100#LA:C071# / 2023 Dec;17(6):1639-1659
000186213 520__ $$aThis study aims to examine the magnitude of out of pocket (OOP) payments and income loss, as well as to identify socioeconomic and clinical factors among long-term breast cancer (BC) survivors in Germany.We examine data from 2654 long-term BC survivors in Germany that participated in the 'CAncEr Survivorship - A multi-Regional population-based study' (CAESAR) and who were at least 5 years post diagnosis. BC-related OOP payments and income loss both within the 12 months prior to the survey were analyzed. Two-part regression models were performed to identify socioeconomic and clinical factors.OOP payments were incurred by 51.9% of survivors with a total mean spending of 566 euros. Income loss was present among 9.6% of survivors and averaged 5463 euros among those reporting such. Socioeconomic and clinical factors associated with higher OOP payments (p ≤ 0.05) included age at time of diagnosis (65-79 years), education (10-11 years), (early) retirement, stage of diagnosis (stage III), time from diagnosis (more than 10 years), comorbidities (at least 1), and the use of rehabilitation services. Regarding income loss, age at time of diagnosis (50-59 years), (early) retirement, stage of diagnosis (stage II), time from diagnosis (5-7 years), comorbidities (at least 1), and receiving chemotherapy treatment were associated with higher losses.For some survivors in Germany, financial burden can be considerably high despite comprehensive healthcare and support from social security.OOP payments related to domestic help and nursing staff as well as to outpatient care are most frequent.
000186213 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186213 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186213 650_7 $$2Other$$aBreast cancer
000186213 650_7 $$2Other$$aFinancial burden
000186213 650_7 $$2Other$$aIncome loss
000186213 650_7 $$2Other$$aLong-term survivors
000186213 650_7 $$2Other$$aOOP payments
000186213 650_7 $$2Other$$aPopulation-based study
000186213 7001_ $$00000-0002-7677-549X$$aHernandez, Diego$$b1
000186213 7001_ $$agroup, CAESAR study$$b2$$eCollaboration Author
000186213 7001_ $$0P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aSchlander, Michael$$b3$$udkfz
000186213 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b4$$eLast author$$udkfz
000186213 7001_ $$agroup, CEASAR study$$b5$$eCollaboration Author
000186213 773__ $$0PERI:(DE-600)2388888-X$$a10.1007/s11764-022-01293-x$$n6$$p1639-1659$$tJournal of cancer survivorship$$v17$$x1932-2259$$y2023
000186213 8767_ $$8V52536$$92023-12-01$$d2024-12-30$$eHybrid-OA$$jZahlung erfolgt
000186213 909CO $$ooai:inrepo02.dkfz.de:186213$$pVDB$$pOpenAPC$$popenCost
000186213 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2f71c86de1a231d82abb4322a95e172a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186213 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-7677-549X$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000186213 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000186213 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000186213 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186213 9141_ $$y2022
000186213 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000186213 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-09$$wger
000186213 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-09
000186213 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-09
000186213 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER SURVIV : 2022$$d2023-08-25
000186213 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000186213 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000186213 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000186213 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000186213 9201_ $$0I:(DE-He78)C100-20160331$$kC100$$lGesundheitsökonomie$$x0
000186213 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x1
000186213 9200_ $$0I:(DE-He78)C100-20160331$$kC100$$lGesundheitsökonomie$$x0
000186213 980__ $$ajournal
000186213 980__ $$aVDB
000186213 980__ $$aI:(DE-He78)C100-20160331
000186213 980__ $$aI:(DE-He78)C071-20160331
000186213 980__ $$aUNRESTRICTED
000186213 980__ $$aAPC